Access options
Subscribe to Journal
Get full journal access for 1 year
$209.00
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1
Reardon DA et al. (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24: 1253–1265
- 2
Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30 (Suppl 19): S10–S14
- 3
Jaeckle KA et al. (2006) Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 24: 1246–1252
- 4
Macdonald DR et al. (1990) Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27: 573–574
- 5
Ino Y et al. (2000) Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92: 983–990
Acknowledgements
The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.
Author information
Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Gilbert, M., Lang, F. Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?. Nat Rev Neurol 3, 14–15 (2007). https://doi.org/10.1038/ncpneuro0375
Received:
Accepted:
Issue Date: